Abstract
The emergence of the primary and acquired drug resistance mutations (DRM) poses a significant threat to successful antiretroviral therapy (ART) against HIV-infection. The WHO/UNAIDS 90–90–90 targets [1] are that 90% of the people living with HIV (PLHIV) know their HIV-status, and, of them, 90% are accessing therapy; finally, of those who are accessing treatment, 90% should have suppressed viral loads. The success of this strategy highly depends on the prevention and monitoring of the pretreatment drug resistance (PDR) and acquired drug resistance (ADR).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have